1429 results for 'resist'

Cancer DevelopmentCancer is a group of diseases that involves abnormal cell growth resulting in malignant tumours/ malignant neoplasms. Cancer is a leading cause of morbidity, with 14 million ne

Quick Info Section: Key Facts About PlozalizumabWhat is Plozalizumab?Plozalizumab is an investigational monoclonal antibody that targets CD47, a key immune checkpoint in cancer cells. By

Targeting USP22: A New Approach to Enhance Anticancer Immunity Introduction In the ever-evolving landscape of cancer research, the intricate relationship between immune e

Quick Facts About TidutamabWhat is Tidutamab?Tidutamab is a monoclonal antibody designed to target somatostatin receptor 2 (SSTR2), a key protein involved in various neuroendocrine tumor

Platinum based cancer drugs Despite nearly 50% of all anti-cancer treatments being platinum-based, there is an urgent need to develop novel therapeutics

Quick Facts About CetuximabWhat is Cetuximab?Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), widely used in cancer therapy.How does Cetuximab wor

Quick Facts About AvizakimabWhat is Avizakimab?Avizakimab is a monoclonal antibody designed to target the CD47 protein, a key checkpoint in immune regulation, particularly in cancer ther

Quick Facts About LacnotuzumabWhat is Lacnotuzumab?Lacnotuzumab is a monoclonal antibody targeting CD47, a protein that helps cancer cells evade immune system destruction.What is the mec

PD-L1 in Cancer Immunotherapy: Insights from Recent ResearchRecent advancements in cancer immunotherapy have underscored the critical role of programmed death-ligand 1 (PD-L1) in mediating immune evas

Enhancing Cancer Research: Syngeneic Mouse Models and Immune Checkpoint Inhibitors A quick guide to Syngeneic Mouse Models Syngeneic Mouse Models Cancer research has seen rema

Cancer immunotherapy has revolutionized the treatment landscape for various malignancies. One of the most promising therapeutic strategies is the use of immune checkpoint inhibitors, part

Cancer immunotherapy has revolutionized oncology, offering powerful new ways to treat various malignancies by harnessing the body's own immune system. Central to this success are immune checkpoint inh

Quick Facts About FletikumabWhat is Fletikumab?Fletikumab is an investigational monoclonal antibody targeting CD47, a key immune checkpoint that enables cancer cells to evade immune dest

Imagine a future where a simple blood test could detect cancer in its earliest stages, long before symptoms appear. This isn't science fiction; it's the rapidly advancing reality of liquid biopsy, a r

Quick Facts About BevacizumabWhat is Bevacizumab?Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), inhibiting angiogenesis (the formation of ne

Quick Facts About TrastuzumabWhat is Trastuzumab?Trastuzumab is a monoclonal antibody used to treat HER2-positive breast and gastric cancers. It specifically targets the HER2 protein, re

Quick Facts About UlocuplumabWhat is Ulocuplumab?Ulocuplumab is an investigational monoclonal antibody targeting CXCR4, a chemokine receptor involved in tumor progression and immune cell

Myrna Hurtado, PhD Student, University of North Texas Health Science Center Advancements in modern medicine have resulted in significantly prolonging and a

Cell Signalling · MetabolismInsulin Signalling & Receptor Tyrosine KinasesInsulin controls metabolism and growth through the insulin receptor — a receptor tyrosine kinase that branches into the